Public Sector Pension Investment Board Acquires 25,221 Shares of Vericel Corporation $VCEL

Public Sector Pension Investment Board boosted its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 14.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 196,863 shares of the biotechnology company’s stock after buying an additional 25,221 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.39% of Vericel worth $6,195,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in VCEL. CWM LLC grew its position in shares of Vericel by 101.3% during the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 694 shares during the period. AlphaQuest LLC purchased a new position in Vericel during the second quarter valued at $60,000. Osaic Holdings Inc. grew its holdings in Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 353 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Vericel by 178.4% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 2,077 shares during the period. Finally, State of Wyoming boosted its position in shares of Vericel by 18.2% in the third quarter. State of Wyoming now owns 6,061 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 933 shares during the period.

Wall Street Analysts Forecast Growth

VCEL has been the subject of several research analyst reports. Truist Financial cut their target price on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Zacks Research lowered shares of Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Vericel Stock Up 1.6%

NASDAQ:VCEL opened at $37.41 on Thursday. The firm has a 50 day moving average of $36.93 and a 200 day moving average of $36.08. Vericel Corporation has a 52 week low of $29.24 and a 52 week high of $58.16. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 155.88 and a beta of 1.24.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.